COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

1 . A compound of Formula I:

or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein:

X 1 is selected from the group consisting of O, S, N, NR 2 , and CR 5 ;

X 2 is selected from the group consisting of O, S, N, NR 4 , and CR 5 ;

each is independently a single bond or a double bond, provided that the five-membered ring comprising X 1 and X 2 is heteroaryl; and

the 6-membered ring

is aromatic;

Q-A is defined according to (A) or (B) below:

(A)

Q is selected from the group consisting of: NH and N(C 1-6 alkyl) wherein the C 1-6 alkyl is optionally substituted with 1-2 independently selected R a ; and

A is:

(i) —(Y A1 ) n —Y A2 , wherein:

n is 0 or 1;

Y A1 is C1-6 alkylene, which is optionally substituted with 1-6 substituents each independently selected from the group consisting of:

oxo;

R a ;

C 6-10 aryl optionally substituted with 1-4 independently selected C 1-4 alkyl; and

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected C 1-4 alkyl; or

Y A1 is —Y A3 —Y A4 —Y A5 which is connected to Q via Y A3 wherein:

Y A3 is a C 1-3 alkylene optionally substituted with 1-2 substituents each independently selected from the group consisting of oxo and R a ;

Y A4 is —O—, —NH—, —N(C 1-6 alkyl)-, or —S—; and

Y A5 is a bond or C 1-3 alkylene which is optionally substituted with 1-2 independently selected R a ; and

Y A2 is:

(a) C 3-20 cycloalkyl or C 3-20 cycloalkenyl, each of which is optionally substituted with 1-4 R b ,

(b) C 6-20 aryl which is optionally substituted with 1-4 R c ;

(c) heteroaryl of 5-20 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), 0, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ; or

(d) heterocyclyl or heterocycloalkenyl of 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl or heterocycloalkenyl ring is optionally substituted with 1-4 independently selected R b ,

or

(ii) —Z 1 —Z 2 —Z 3 , wherein:

Z 1 is C 1-3 alkylene, which is optionally substituted with 1-4 R a ;

Z 2 is —N(H)—, —N(R d )—, —O—, or —S—; and

Z 3 is C 2-7 alkyl, which is optionally substituted with 1-4 R a ;

or

(iii) C 1-20 alkyl, which is optionally substituted with 1-6 independently selected R a , or

(B)

Q and A, taken together, form:

 and

E is a ring of 3-16 ring atoms, wherein 0-3 ring atoms are heteroatoms (in addition to the nitrogen atom this is already present), each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the ring is optionally substituted with 1-4 independently selected R b ,

each of R 1a , R 1b , R 1c , and R 1d is independently selected from the group consisting of: H; halo; cyano; C 1-6 alkyl optionally substituted with 1-2 R a ; C 2-6 alkenyl; C 2-6 alkynyl; C 1-4 haloalkyl; C 1-4 alkoxy; C 1-4 haloalkoxy; -L 3 -L 4 -R i ; —S(O) 1-2 (C 1-4 alkyl); —S(O)(═NH)(C 1-4 alkyl); SF 5 ; —NR e R f ; —OH; oxo; —S(O) 1-2 (NR′R″); —C 1-4 thioalkoxy; —NO 2 ; —C(═O)(C 1-4 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; and —C(═O)N(R′)(R″); or

R 1a and R 1b , R 1b and R 1c , or R 1c and R 1d , taken together with the atoms connecting them, form a ring of 3-10 ring atoms, wherein 0-2 ring atoms are heteroatoms each independently selected from the group consisting of N, N(H), N(R d ), 0, and S(O) 0-2 ; and wherein the ring is optionally substituted with 1-4 substituents each independently selected from the group consisting of C 1-6 alkyl, halo, C 1-6 haloalkyl, —OH, NR e R f , C1-6 alkoxy, and C 1-6 haloalkoxy,

each occurrence of R 2 is independently selected from the group consisting of:

(i) C 1-6 alkyl, which is optionally substituted with 1-2 independently selected R a ;

(ii) C 3-6 cycloalkyl or C 3-6 cycloalkenyl;

(iii) heterocyclyl or heterocycloalkenyl of 3-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), 0, and S(O) 0-2 ;

(iv) C 6-10 aryl;

(v) heteroaryl of 5-10 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 ;

(vi) —C(O)(C 1-4 alkyl);

(vii) —C(O)O(C1.4 alkyl);

(viii) —CON(R′)(R″);

(ix) —S(O)i-2(NR′R″);

(x) —S(O) 1-2 (C 1-4 alkyl);

(xi) —OH;

(xii) C 1-4 alkoxy; and

(xiii) H;

R 4 is selected from the group consisting of H and C 1-6 alkyl optionally substituted with 1-3 independently selected R a ;

R 5 is selected from the group consisting of H; halo; —OH; —C 1-4 alkyl; —C 1-4 haloalkyl;

C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)O(C 1-4 alkyl); —C(═O)(C 1-4 alkyl); —C(═O)OH; —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano; and C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-4 independently selected C 1-4 alkyl;

R 6 is selected from the group consisting of H; C 1-6 alkyl optionally substituted with 1-3 independently selected R a ; —OH; C 1-4 alkoxy; C(═O)H; C(═O)(C 1-4 alkyl); C 6-10 aryl optionally substituted with 1-4 independently selected C 1-4 alkyl; and heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected C 1-4 alkyl;

each occurrence of R a is independently selected from the group consisting of: —OH; —F; —Cl; —Br; —NR I R f ; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)O(C 1-4 alkyl); —C(═O)(C 1-4 alkyl); —C(═O)OH; —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano, and C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-4 independently selected C 1-4 alkyl;

each occurrence of R b is independently selected from the group consisting of: C 1-10 alkyl optionally substituted with 1-6 independently selected R a ; C 1-4 haloalkyl; —OH; oxo; —F; —Cl; —Br; —NR e R f ; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)O(C 1-4 alkyl); —C(═O)OH; —C(═O)N(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); cyano; and -L 1 -L 2 -R h ;

each occurrence of R c is independently selected from the group consisting of: halo;

cyano; C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkenyl; C 2-6 alkynyl; oxo; C 1-4 alkoxy optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkoxy; —S(O) 1-2 (C 1-4 alkyl) or —S(O) 1-2 (C 1-4 haloalkyl); —NR e R f ; —OH; —S(O) 1-2 (NR′R″); —C 1-4 thioalkoxy or —C 1-4 thiohaloalkoxy; —NO 2 ; —SF 5 ; —C(═O)(C 1-10 alkyl); —C(═O)O(C1-4 alkyl); —C(═O)OH; —C(═O)N(R′)(R″); and -L 1 -L 2 -R h ;

R d is selected from the group consisting of: C 1-6 alkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of halo and OH; C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each optionally substituted with 1-3 substituents each independently selected from the group consisting of halo and OH; —C(O)(C 1-4 alkyl); —C(O)O(C 1-4 alkyl); —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); —OH; and C 1-4 alkoxy;

each occurrence of R e and R f is independently selected from the group consisting of: H; C 1-6 alkyl; C 1-6 haloalkyl; C 3-6 cycloalkyl or C 3-6 cycloalkenyl; —C(O)(C 1-4 alkyl); —C(O)O(C 1-4 alkyl); —CON(R′)(R″); —S(O) 1-2 (NR′R″); —S(O) 1-2 (C 1-4 alkyl); —OH; and C 1-4 alkoxy; or R e and R f together with the nitrogen atom to which each is attached forms a ring of 3-8 ring atoms, wherein the ring has: (a) 1-7 ring carbon atoms, each of which is substituted with 1-2 substituents independently selected from the group consisting of H and C 1-3 alkyl; and (b) 0-3 ring heteroatoms (in addition to the nitrogen atom attached to R e and Rr), which are each independently selected from the group consisting of N(R d ), NH, 0, and S;

-L 1 is a bond or C 1-3 alkylene;

-L 2 is —O—, —N(H)—, —N(C 1-3 alkyl)-, —S(O) 0-2 -, or a bond;

R h is selected from the group consisting of:

C 3-8 cycloalkyl or C 3-8 cycloalkenyl, each optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heterocyclyl or heterocycloalkenyl, wherein the heterocyclyl or heterocycloalkenyl has 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , wherein the heterocyclyl or heterocycloalkenyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

C 6-10 aryl, which is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

-L 3 is a bond or C 1-3 alkylene;

-L 4 is —O—, —N(H)—, —N(C 1-3 alkyl)-, —S(O) 0-2 -, or a bond;

R i is selected from the group consisting of:

C 3-8 cycloalkyl or C 3-8 cycloalkenyl, each optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heterocyclyl or heterocycloalkenyl, wherein the heterocyclyl or heterocycloalkenyl has 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , wherein the heterocyclyl or heterocycloalkenyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy;

heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

C 6-10 aryl, which is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

each occurrence of R′ and R″ is independently selected from the group consisting of: H, C 1-4 alkyl, C 6-10 aryl optionally substituted with 1-2 substituents selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl, and heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo, —OH, NH 2 , NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , C 1-4 alkyl, and C 1-4 haloalkyl; or R′ and R″ together with the nitrogen atom to which each is attached forms a ring of 3-8 ring atoms, wherein the ring has: (a) 1-7 ring carbon atoms, each of which is substituted with 1-2 substituents independently selected from the group consisting of H and C 1-3 alkyl; and (b) 0-3 ring heteroatoms (in addition to the nitrogen atom attached to R′ and R″), which are each independently selected from the group consisting of N(H), N(C 1-6 alkyl), O, and S.

2 . The compound of claim 1 , wherein X 1 is NR 2 , optionally wherein R 2 is H.

3 . The compound of claim 1 or 2 , wherein X 2 is CR 5 , optionally wherein R 5 is H.

4 . The compound of any one of claims 1 - 3 , wherein the

moiety is

wherein each of R 1b , R 1c , and R 1d in the above formulae is an independently selected substituent that is other than H, optionally wherein each of R 1b , R 1c , and R 1d is an independently selected halo, such as —F or —Cl.

5 . The compound of any one of claims 1 - 4 , wherein Q-A is defined according to (A).

6 . The compound of any one of claims 1 - 5 , wherein A is —(Y A1 ) n —Y A2 .

7 . The compound of any one of claims 1 - 6 , wherein Y A2 is C 6-10 aryl, which is optionally substituted with 1-3 R c ; or

wherein Y A2 is heteroaryl of 5-14 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and

wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ; or

wherein Y A2 is monocyclic C 3-10 cycloalkyl or C3-10 cycloalkenyl, each of which is optionally substituted with 1-4 R b ; or

wherein Y A2 is heterocyclyl or heterocycloalkenyl of 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl or heterocycloalkenyl ring is optionally substituted with 1-3 independently selected R b .

8 . The compound of any one of claims 1 - 7 , wherein Y A2 is C 3-6 cycloalkyl or C 3-6 cycloalkenyl, each of which is substituted with 1-4, such as 1-2, R b , such as:

wherein Y A2 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted with 1-2 R b , such as:

wherein Y A2 is

9 . The compound of any one of claims 1 - 7 , wherein Y A2 is heterocyclyl or heterocycloalkenyl of 3-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl or heterocycloalkenyl ring is optionally substituted with 1-3 independently selected R b , such as:

wherein Y A2 is heterocyclyl of 4-8 ring atoms, such as 4-6 ring atoms, wherein 1-2 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl ring is optionally substituted with 1-2 independently selected R b , such as:

wherein Y A2 is

wherein m1 and m2 are independently 0, 1, or 2, such as: wherein Y A2 is

10 . The compound of any one of claims 1 - 9 , wherein each occurrence of R b is independently selected from the group consisting of: C 1-10 alkyl optionally substituted with 1-6 independently selected R a ; C 1-4 haloalkyl; —F; —Cl; —Br; cyano; C 1-4 alkoxy; C 1-4 haloalkoxy; —C(═O)(C 1-10 alkyl); —C(═O)O(C 1-4 alkyl); —S(O) 1-2 (C 1-4 alkyl); oxo; cyano; and -L 1 -L 2 -R h ,

optionally wherein one occurrence of R b is -L 1 -L 2 -R h ,

optionally wherein L 1 is a bond, and L 2 is —O— or a bond; and

optionally wherein R h is C 6-10 aryl, which is optionally substituted with 1-4 substituents independently selected from the group consisting of halo, C 1-4 alkyl, and C 1-4 haloalkyl; or

wherein R h is heteroaryl of 5-10 ring atoms, wherein 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 and wherein the heteroaryl ring is optionally substituted with 1-4 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy.

11 . The compound of any one of claims 1 - 4 , wherein Q-A is as defined according to (B).

12 . The compound of claim 1 , wherein the compound is a compound of Formula (I-1), (I-2), (I-3), (I-4), or (I-5), or a pharmaceutically acceptable salt thereof:

wherein n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl;

wherein n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl;

wherein one of Q 1 and Q 2 is N; the other one of Q 1 and Q 2 is CH; n1 is 0, 1, or 2; each of R cA and R cB is an independently selected R c ; and R 7 is H or C1.4 alkyl;

wherein one of Q 1 , Q 2 , Q 3 , and Q 4 is N; each of the remaining of Q 1 , Q 2 , Q 3 , Q 4 is CH; n1 is 0, 1, or 2; and each of R cA and R cB is an independently selected R c ; and R 7 is H or C 1-4 alkyl; or

wherein B 1 is selected from the group consisting of:

(a) bicyclic or tricyclic heteroaryl of 7-14 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heteroaryl ring is optionally substituted with 1-4 independently selected R c ; and

(b) C 7-10 bicyclic aryl, which is optionally substituted with 1-3 R c , and

R 7 is H or C 1-4 alkyl;

optionally wherein X 1 is NH; and X 2 is CH in Formula (I-1), (I-2), (I-3), (I-4), or (I-5); and

optionally wherein R cA in Formula (I-1), (1-2), (1-3), or (I-4) is selected from the group consisting of: C 1-10 alkyl which is optionally substituted with 1-6 independently selected R a ; C 2-6 alkynyl; C 1-4 alkoxy; C 1-4 haloalkoxy; and -L 1 -L 2 -R h .

13 . The compound of claim 1 , wherein the compound is a compound of Formula (I-6), (I-7), (I-11), (I-12), or (I-8), or a pharmaceutically acceptable salt thereof:

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl;

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl;

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl;

wherein n2 is 0, 1, or 2; each of R bA and R bB is an independently selected R b ; and R 7 is H or C 1-4 alkyl;

wherein B 2 is selected from the group consisting of:

bicyclic, tricyclic, or polycyclic C 7-20 cycloalkyl or C 7-20 cycloalkenyl, each optionally substituted with 1-2 independently selected R b ; and

bicyclic, tricyclic, or polycyclic heterocyclyl of 8-16 ring atoms, wherein 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(H), N(R d ), O, and S(O) 0-2 , and wherein the heterocyclyl ring is optionally substituted with 1-4 independently selected R b , and

R 7 is H or C 1-4 alkyl,

optionally wherein X 1 is NH; and X 2 is CH in Formula (I-6), (I-7), (I-11), (I-12), or (I-8); and

optionally wherein R bA is —R h in Formula (I-6), (I-7), (I-11), or (I-12), such as wherein R bA is: -L 1 -L 2 -R h , such as —R h or —O—R h , and

optionally wherein R h is selected from the group consisting of:

heteroaryl of 6 ring atoms, wherein 1-2 ring atoms are ring nitrogen atoms and wherein the heteroaryl ring is optionally substituted with 1-2 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy; and

C 6 aryl, which is optionally substituted with 1-2 substituents independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy.

14 . The compound of any one of claims 1 - 13 , wherein n is 0.

15 . The compound of claim 1 , wherein the compound is a compound of Formula (I-13):

wherein:

m1 and m2 are independently 0, 1, or 2;

Q 5 is N or CH;

L 5 is a bond, CH 2 , —O—, —N(H)—, or —N(C 1-3 alkyl), provided that when Q 5 is N, then L 5 is a bond or CH 2 ;

T 1 , T 2 , T 3 , and T 4 are each independently N, CH, or CR t , provided that 1-4, such as 2, 3, or 4, of T 1 -T 4 is CH; and

each of R t and R s is independently selected from the group consisting of halo; C 1-4 alkyl optionally substituted with 1-2 independently selected R a ; C 1-4 haloalkyl; cyano; C 1-4 alkoxy; and C 1-4 haloalkoxy,

optionally wherein R 2 is H, and R 5 is H; and

optionally wherein R 1b is halo, such as —F or —Cl; R 1c is H or halo, such as —H or —F; and R 1a and R 1d are H.

16 . The compound of claim 1 , wherein the compound is selected from the group consisting of the compounds delineated in Table C1, or a pharmaceutically acceptable salt thereof.

17 . A pharmaceutical composition comprising a compound of claims 1 - 16 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

18 . A method for inhibiting STING activity, the method comprising contacting STING with a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition as claimed in claim 17 .

19 . A method of inducing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof; or a pharmaceutical composition as claimed in claim 17 .

20 . A method of treatment of disease, disorder, or condition associated with STING, such as a disease, disorder, or condition, in which increased STING signaling, such as excessive STING signaling, contributes to the pathology and/or symptoms and/or progression of the disease, such as cancer, comprising administering to a subject in need of such treatment an effective amount of a compound as claimed in any one of claims 1 - 16 , or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as claimed in claim 17 .